Plexxikon – Scaffold-Based Drug Discovery

Plexxikon

Scaffold-Based Drug Discovery

  • Cardio-Renal
  • CNS
  • Inflammation
  • Metabolic Disease
  • Oncology
  • Cardio-Renal
  • CNS
  • Inflammation
  • Metabolic Disease
  • Oncology
  • About
    • Management
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Cardio-Renal
    • CNS
    • Inflammation
    • Metabolic Disease
    • Oncology
  • Clinical Trials
  • Partners
    • Partnering Opportunities
    • Partnerships
  • Investors
  • News
    • Press Releases
    • Plexxikon in the News
    • Press Kit
  • Careers
  • Contact Us
    • Driving Directions
08/25/2010
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate in Metastatic Melanoma Patients in the New England Journal of Medicine
07/14/2010
Plexxikon's Novel Agent Significantly Inhibits Activation of Key CNS Cells Associated With Alzheimer's Disease
06/06/2010
PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported
© Plexxikon 2010     Website design: Hane Chow Inc.